ArticleFrontiers in oncology2023

TPD52L2 as a potential prognostic and immunotherapy biomarker in clear cell renal cell carcinoma.

Hongbo Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.